Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 74, Issue 2, Pages 396-401
Publisher
BMJ
Online
2013-12-11
DOI
10.1136/annrheumdis-2013-204185
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study
- (2014) Nobuyuki Miyasaka et al. Modern Rheumatology
- Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation
- (2013) Pauline A van Schouwenburg et al. ANNALS OF THE RHEUMATIC DISEASES
- Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
- (2012) Fabien B Vincent et al. ANNALS OF THE RHEUMATIC DISEASES
- Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
- (2012) Charlotte L Krieckaert et al. ANNALS OF THE RHEUMATIC DISEASES
- The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
- (2012) Sandra Garcês et al. ANNALS OF THE RHEUMATIC DISEASES
- Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria
- (2012) K. M. Fagerli et al. RHEUMATOLOGY
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Differential effect of drug interference in immunogenicity assays
- (2011) Margreet H. Hart et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing
- (2011) Theo Rispens et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
- (2011) Denis Mulleman et al. ARTHRITIS RESEARCH & THERAPY
- Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores
- (2010) P. Machado et al. ANNALS OF THE RHEUMATIC DISEASES
- Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis
- (2010) D Chu Miow Lin et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review
- (2010) Charlotte Krieckaert et al. ARTHRITIS RESEARCH & THERAPY
- Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation
- (2009) M K de Vries et al. ANNALS OF THE RHEUMATIC DISEASES
- Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control study
- (2009) Roman Krzysiek et al. ARTHRITIS AND RHEUMATISM
- Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid A protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis
- (2009) Mirjam K. de Vries et al. ARTHRITIS AND RHEUMATISM
- Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
- (2009) Denis Mulleman et al. ARTHRITIS RESEARCH & THERAPY
- Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
- (2008) D van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
- Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
- (2008) T R D J Radstake et al. ANNALS OF THE RHEUMATIC DISEASES
- ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis
- (2008) D van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started